ClinicalTrials.gg
CompletedNCT07074327Updated Mar 30, 2026

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

A Phase 1 interventional study of VX-407 and LNG/EE in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.

Enrollment
24th of 63
74 · median 48
Started
2025
with 5 others
Phase 1
10 of 85
2 open now
Registered
78th of 85
by date
Lead sponsor
6 of 85
Vertex Pharmaceuticals Incorporated

Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 24th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2025, is one of 10 in phase 1, and was the 78th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Keywords

  • Oral contraceptives
  • Drug interaction
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m\^2)
  • A total body weight of greater than (>) 50 kg
  • Nonsmoker or ex-smoker for at least 12 months before screening
  • Oral naïve or able to comply with 28-day or 5 half-lives (whichever is greater) before the start of Period 1 (6-month washout for Depo-Provera)

Exclusion criteria

Exclusion Criteria:

  • History of febrile illness within 5 days before the first dose of study drug
  • Relative to hormonal estrogen therapy that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
  • Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
  • Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of study drug
  • Menopausal, , or documented bilateral oophorectomy and/or hysterectomy
  • Previously received study drug in this study

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Part A: VX-407 With Levonorgestrel/Ethinyl Estradiol (LNG/EE)

    Participants will receive a single dose of LNG/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 every 12 hours (q12h) from Days 8 through 26 in fasted state.

    Drug: VX-407 · Drug: LNG/EE

  • Experimental
    Part B (Optional): VX-407 With Norgestimate/Ethinyl Estradiol (NGM/EE)

    Participants will receive a single dose of NGM/EE on Days 1 and 23 in fasted state. Participants will also receive VX-407 q12h from Days 10 through 30 in fasted state.

    Drug: VX-407 · Drug: NGM/EE

  • Experimental
    Part C (Optional): VX-407 With Norethindrone/Ethinyl Estradiol (NET/EE)

    Participants will receive a single dose of NET/EE on Days 1 and 19 in fasted state. Participants will also receive VX-407 q12h from Days 6 through 22 in fasted state.

    Drug: VX-407 · Drug: NET/EE

  • Experimental
    Part D (Optional): VX-407 With Drospirenone/Ethinyl Estradiol (DRSP/EE)

    Participants will receive a single dose of DRSP/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 q12h from Days 8 through 26 in fasted state.

    Drug: VX-407 · Drug: DRSP/EE

Interventions

  • DrugVX-407

    Suspension for oral administration.

  • DrugLNG/EE

    Combination Tablets for Oral Administration.

  • DrugNGM/EE

    Combination Tablets for Oral Administration.

  • DrugNET/EE

    Combination Tablets for Oral Administration.

  • DrugDRSP/EE

    Drug page: Drospirenone

    Combination Tablets for Oral Administration.

06

What researchers measure

Primary outcomes

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of LNG and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27

  2. Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27

  3. Part B (Optional): Cmax of Norelgestromin (NGMN) and Norgestrel (NG) (Active Metabolites of NGM) and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31

  4. Part B (Optional): AUC0-inf of NGMN and NG (Active Metabolites of NGM) and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31

  5. Part C (Optional): Cmax of NET and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23

  6. Part C (Optional): AUC0-inf of NET and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23

  7. Part D (Optional): Cmax of DRSP and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27

  8. Part D (Optional): AUC0-inf of DRSP and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27

Secondary outcomes

  1. Part A: Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 36

  2. Part B (Optional): Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 40

  3. Part C (Optional): Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 32

  4. Part D (Optional): Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 36

  5. Part A: Cmax of VX-407

    Time frame: Days 9, 15 and 21 up to Day 27

  6. Part A: AUC0-inf of VX-407

    Time frame: Days 9, 15 and 21 up to Day 27

  7. Part B (Optional): Cmax of VX-407

    Time frame: Days 11, 17 and 23 up to Day 31

  8. Part B (Optional): AUC0-inf of VX-407

    Time frame: Days 11, 17 and 23 up to Day 31

  9. Part C (Optional): Cmax of VX-407

    Time frame: Days 7, 13 and 19 up to Day 23

  10. Part C (Optional): AUC0-inf of VX-407

    Time frame: Days 7, 13 and 19 up to Day 23

  11. Part D (Optional): Cmax of VX-407

    Time frame: Days 9, 15 and 21 up to Day 27

  12. Part D (Optional): AUC0-inf of VX-407

    Time frame: Days 9, 15 and 21 up to Day 27

07

Study locations

1 site
  • Altasciences - Kansas City
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Feb 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 20, 2025
StartActual
Jul 11, 2025
Primary completionActual
Feb 20, 2026
CompletionActual
Feb 27, 2026
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07074327
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Jul 11, 2025
Primary completion
Feb 20, 2026
Completion
Feb 27, 2026
Last update
Mar 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VX-407

Start the discussion